Executive Vice President and Deputy Director
Clinical Research Division, Fred Hutch
Dr. Fred Appelbaum studies the biology and treatment of leukemias, lymphomas and other blood cancers and sees patients with these disorders. He has made numerous landmark contributions to his field. Notably, he helped develop Fred Hutch’s renowned program in blood stem cell transplantation. He also participated in the Hutch’s pioneering work to develop targeted antibody-based cancer therapies. Today, Dr. Appelbaum leads Fred Hutch’s Adult Leukemia Research Center and the Hematologic Malignancy Program of the Fred Hutchinson/University of Washington Cancer Consortium. These efforts are aimed at enhancing our understanding of these diseases and improving treatments like blood stem cell transplantation. As Fred Hutch deputy director, Dr. Appelbaum leads the implementation of key scientific strategies and partnerships. He also helps to ensure that Fred Hutch advances are shared with the wider community.
Dr. Appelbaum was the lead author of the first paper to describe the successful use of autologous bone marrow transplantation, a therapy now used in more than 30,000 patients annually. He was also a key contributor to the discovery and development of gemtuzumab ozogamicin, known commercially as Mylotarg, the first antibody-drug conjugate approved by the Food and Drug Administration.
Professor, Division of Medical Oncology
University of Washington
M.D., Tufts University, 1972
A.B. (cum laude), Dartmouth College, 1968
Study Number: EAY131
— Dr. Fred Appelbaum
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email firstname.lastname@example.org or call 206.667.2210.